“Production of SARS-CoV-2 pseudotyped viral particles for the evaluation of new therapies against COVID-19” (2022) FAVE Sección Ciencias Veterinarias, 20(Suppl.), pp. 44–50. doi:10.14409/favecv.2021.Suppl. 44-50.